3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
2
Phase 2/3
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Neoplasm Metastasis
3
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Melanoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Graft vs Host Disease
1
Ganglioneuroblastoma
1
Endometrial Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
pembrolizumab
74
Nivolumab
53
Ipilimumab
42
Cyclophosphamide
32
Interleukin-2
24
aldesleukin
23
Temozolomide
17
fludarabine
16
Biopsy
11
trametinib
10
fludarabine phosphate
10
dabrafenib
10
spartalizumab
8
Paclitaxel
8
Dacarbazine
8
sargramostim
7
cemiplimab
7
binimetinib
7
Cisplatin
7
Bevacizumab
7
poly ICLC
6
lenvatinib
6
epacadostat
6
Radiotherapy
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
montanide ISA 51
5
encorafenib
5
atezolizumab
5
Vemurafenib
5
Specimen Handling
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Melanoma
×
Colony-Stimulating Factors
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled